|
|
|
DAR File No. 27747 |
|
| This filing was published in the 04/01/2005, issue, Vol. 2005, No. 7, of the Utah State Bulletin. | |
| [ 04/01/2005 Bulletin Table of Contents / Bulletin Page ] | |
|
Environmental Quality, Radiation Control R313-22 Specific Licenses
|
|
NOTICE OF PROPOSED RULE |
|
|
DAR File No.: 27747
|
|
RULE ANALYSIS |
|
Purpose of the rule or reason for the change: |
|
|
The reason for this change is to modify Utah's Radiation Control Rules to be compatible with the federal requirements found in 10 CFR 32.
|
|
Summary of the rule or change: |
|
|
This rule change modifies references to Rule R313-32 which is being modified in its entirety. Specifically, it corrects references to the training and experience criteria for persons preparing radioactive drugs for medical use and corrects references to specific medical uses. (DAR NOTE: The proposed amendment to Rule R313-32 is under DAR No. 27748 in this issue.)
|
|
State statutory or constitutional authorization for this rule: |
|
|
Sections 19-3-104 and 19-3-108
|
|
| This rule or change incorporates by reference the following material: | |
|
10 CFR 35
|
|
Anticipated cost or savings to: |
|
the state budget: |
|
|
No additional regulatory requirements will need to be implemented by the state. Therefore, the rule changes will not result in a cost or savings to the state budget.
|
|
local governments: |
|
|
The rule modification does not affect the local governments presently licensed under the rules under R313. Therefore, there will be no cost or savings for local governments.
|
|
other persons: |
|
|
No additional regulatory requirements will need to be implemented by affected persons due to the rule changes. Therefore, there will be no cost or savings for affected persons.
|
|
Compliance costs for affected persons: |
|
|
No additional regulatory requirements will need to be implemented by affected persons due to the rule changes. Therefore, there will be no cost or savings for affected persons.
|
|
Comments by the department head on the fiscal impact the rule may have on businesses: |
|
|
This rule change will have no fiscal impact on businesses. Dianne R. Nielson, Executive Director
|
|
The full text of this rule may be inspected, during regular business hours, at the Division of Administrative Rules, or at: |
|
|
Environmental Quality Radiation Control 168 N 1950 W SALT LAKE CITY UT 84116-3085
|
|
Direct questions regarding this rule to: |
|
|
Gwyn Galloway at the above address, by phone at 801-536-4258, by FAX at 801-533-4097, or by Internet E-mail at ggalloway@utah.gov
|
|
Interested persons may present their views on this rule by submitting written comments to the address above no later than 5:00 p.m. on: |
|
|
05/02/2005
|
|
This rule may become effective on: |
|
|
05/13/2005
|
|
Authorized by: |
|
|
Dane Finerfrock, Director
|
|
RULE TEXT |
|
|
R313. Environmental Quality, Radiation Control. R313-22. Specific Licenses. R313-22-1. Purpose and Authority. (1) The purpose of this rule is to prescribe the requirements for the issuance of specific licenses. (2) The rules set
forth herein are adopted pursuant to the provisions of Subsections 19-3-104([
R313-22-75. Special Requirements for a Specific License to Manufacture, Assemble, Repair, or Distribute Commodities, Products, or Devices Which Contain Radioactive Material. (1) Licensing the introduction of radioactive material into products in exempt concentrations.
. . . . . . .
(9) Manufacture and distribution of radiopharmaceuticals containing radioactive material for medical use under group licenses. (a) An application for a specific license to manufacture and distribute radiopharmaceuticals containing radioactive material for use by persons licensed pursuant to Rule R313-32 will be approved if: (i) the applicant satisfies the general requirements specified in Section R313-22-33; (ii) the applicant submits evidence that the applicant is at least one of the following: (A) registered or licensed with the U.S. Food and Drug Administration (FDA) as a drug manufacturer; (B) registered or licensed with a state agency as a drug manufacturer; (C) licensed as a pharmacy by a State Board of Pharmacy; or (D) operating as a nuclear pharmacy within a medical institution. (iii) the applicant submits information on the radionuclide; the chemical and physical form; the maximum activity per vial, syringe, generator, or other container of the radioactive drug; and the shielding provided by the packaging to show it is appropriate for the safe handling and storage of the radioactive drugs by medical use licensees; and (iv) the applicant satisfies the following labeling requirements: (A) A label is affixed to each transport radiation shield, whether it is constructed of lead, glass, plastic, or other material, of a radioactive drug to be transferred for commercial distribution. The label must include the radiation symbol and the words "CAUTION, RADIOACTIVE MATERIAL" or "DANGER, RADIOACTIVE MATERIAL"; the name of the radioactive drug or its abbreviation; and the quantity of radioactivity at a specified date and time. For radioactive drugs with a half life greater than 100 days, the time may be omitted. (B) A label is affixed to each syringe, vial, or other container used to hold a radioactive drug to be transferred for commercial distribution. The label must include the radiation symbol and the words "CAUTION, RADIOACTIVE MATERIAL" or "DANGER, RADIOACTIVE MATERIAL" and an identifier that ensures that the syringe, vial, or other container can be correlated with the information on the transport radiation shield label. (b) A licensee described by Subsections R313-22-75(9)(a)(ii)(C) or (D): (i) May prepare
radioactive drugs for medical use, as defined in [ (ii) May allow a pharmacist to work as an authorized nuclear pharmacist if: (A) this
individual qualifies as an authorized nuclear pharmacist as defined in [ (B) this
individual meets the requirements specified in [ (C) this
individual is designated as an authorized nuclear pharmacist in accordance with
Subsection R313-22-75(9)(b)[ (iii) The actions authorized in Subsections R313-22-75(9)(b)(i) and (ii) are permitted in spite of more restrictive language in license conditions. (iv) May
designate a pharmacist, as defined in [ (v) Shall provide to the Executive Secretary a copy of each individual's certification by the Board of Pharmaceutical Specialties, the Nuclear Regulatory Commission or Agreement State license, or the permit issued by a licensee of broad scope, and a copy of the state pharmacy licensure or registration, no later than 30 days after the date that the licensee allows, pursuant to Subsections R313-22-75(9)(b)(ii)(A) and (B), the individual to work as an authorized nuclear pharmacist. (c) A licensee shall possess and use instrumentation to measure the radioactivity of radioactive drugs. The licensee shall have procedures for use of the instrumentation. The licensee shall measure, by direct measurement or by combination of measurements and calculations, the amount of radioactivity in dosages of alpha-, beta-, or photon-emitting radioactive drugs prior to transfer for commercial distribution. In addition, the licensee shall: (i) perform tests before initial use, periodically, and following repair, on each instrument for accuracy, linearity, and geometry dependence, as appropriate for the use of the instrument; and make adjustments when necessary; and (ii) check each instrument for constancy and proper operation at the beginning of each day of use. (d) Nothing in Subsection R313-22-75(9) relieves the licensee from complying with applicable FDA, or Federal, and State requirements governing radioactive drugs. (10) Manufacture
and distribution of sources or devices containing radioactive material for
medical use. An application for a
specific license to manufacture and distribute sources and devices containing
radioactive material to persons licensed pursuant to [ (a) the applicant satisfies the general requirements in Section R313-22-33; (b) the applicant submits sufficient information regarding each type of source or device pertinent to an evaluation of its radiation safety, including: (i) the radioactive material contained, its chemical and physical form and amount, (ii) details of design and construction of the source or device, (iii) procedures for, and results of, prototype tests to demonstrate that the source or device will maintain its integrity under stresses likely to be encountered in normal use and accidents, (iv) for devices containing radioactive material, the radiation profile of a prototype device, (v) details of quality control procedures to assure that production sources and devices meet the standards of the design and prototype tests, (vi) procedures and standards for calibrating sources and devices, (vii) legend and methods for labeling sources and devices as to their radioactive content, and (viii) instructions for handling and storing the source or device from the radiation safety standpoint, these instructions are to be included on a durable label attached to the source or device or attached to a permanent storage container for the source or device; provided that instructions which are too lengthy for a label may be summarized on the label and printed in detail on a brochure which is referenced on the label; (c) the label
affixed to the source or device, or to the permanent storage container for the
source or device, contains information on the radionuclide, quantity and date
of assay, and a statement that the source or device is licensed by the
Executive Secretary for distribution to persons licensed pursuant to [ (d) in the event the applicant desires that the source or device be required to be tested for leakage of radioactive material at intervals longer than six months, the applicant shall include in the application sufficient information to demonstrate that a longer interval is justified by performance characteristics of the source or device or similar sources or devices and by design features that have a significant bearing on the probability or consequences of leakage of radioactive material from the source; and (e) in determining the acceptable interval for test of leakage of radioactive material, the Executive Secretary shall consider information that includes, but is not limited to: (i) primary containment or source capsule, (ii) protection of primary containment, (iii) method of sealing containment, (iv) containment construction materials, (v) form of contained radioactive material, (vi) maximum temperature withstood during prototype tests, (vii) maximum pressure withstood during prototype tests, (viii) maximum quantity of contained radioactive material, (ix) radiotoxicity of contained radioactive material, and (x) operating experience with identical sources or devices or similarly designed and constructed sources or devices.
. . . . . . .
KEY: specific licenses, decommissioning, broad scope, radioactive materials [ Notice of Continuation October 10, 2001 19-3-104 19-3-108
|
|
ADDITIONAL INFORMATION |
|
|
PLEASE NOTE:
|
|
|
For questions regarding the content or application of this rule, please contact Gwyn Galloway at the above address, by phone at 801-536-4258, by FAX at 801-533-4097, or by Internet E-mail at ggalloway@utah.gov For questions about the rulemaking process, please contact the Division of Administrative Rules (801-538-3764). Please Note: The Division of Administrative Rules is NOT able to answer questions about the content or application of these administrative rules. |
|
| [ 04/01/2005 Bulletin Table of Contents / Bulletin Page ] | |
| Last modified: 06/01/2005 6:08 PM | |